Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 195 Companies   327 Products   327 Products   167 Mechanisms of Action   13 Trials   3266 News 


«12345678910111213...6768»
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, HEOR:  PSY_HaEMOPEQ: Effectiveness of Psychological Interventions in Haemophilia (clinicaltrials.gov) -  Jun 28, 2018   
    P=N/A,  N=20, Active, not recruiting, 
    Not yet recruiting --> Active, not recruiting | N=66 --> 20 | Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  GOCAPXE: What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum (clinicaltrials.gov) -  Jun 28, 2018   
    P=N/A,  N=23, Completed, 
    Not yet recruiting --> Active, not recruiting | N=66 --> 20 | Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018 Recruiting --> Completed | N=17 --> 23 | Trial completion date: Jun 2017 --> Dec 2017 | Trial primary completion date: May 2017 --> Dec 2017
  • ||||||||||  aspirin / Generic mfg.
    Trial completion, Enrollment change:  High-Shear Microfluidic Thrombosis Assay (clinicaltrials.gov) -  Jun 7, 2018   
    P=N/A,  N=16, Completed, 
    Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Sep 2017 --> Dec 2021 Enrolling by invitation --> Completed | N=45 --> 16
  • ||||||||||  CYAD-01 / Celdara Medical, Celyad Oncology
    Trial completion, Trial primary completion date, Metastases:  Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) -  Jun 3, 2018   
    P1,  N=12, Completed, 
    Active, not recruiting --> Completed | N=100 --> 50 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Mar 2018
  • ||||||||||  autologous CD34+ cells transduced with WASP lentiviral vector / Genethon, Boston Children's Hospital
    Trial completion, Gene therapy:  Gene Therapy for WAS (clinicaltrials.gov) -  Jun 2, 2018   
    P1/2,  N=5, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  iTACTIC: Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (clinicaltrials.gov) -  Apr 18, 2018   
    P2,  N=392, Recruiting, 
    Trial completion date: Feb 2018 --> Dec 2018 | Trial primary completion date: Feb 2018 --> Jul 2017 Trial completion date: Jan 2018 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018
  • ||||||||||  gandotinib (LY 2784544) / Eli Lilly
    Trial completion, Trial completion date:  A Study in Myeloproliferative Disorders (clinicaltrials.gov) -  Apr 17, 2018   
    P1,  N=80, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2018
  • ||||||||||  Trial completion date, Trial primary completion date:  HeL-Fascial: Fascial Therapy in Elbow Hemophilic Arthropathy (clinicaltrials.gov) -  Apr 10, 2018   
    P=N/A,  N=60, Recruiting, 
    Active, not recruiting --> Completed | N=60 --> 34 Trial completion date: Oct 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Dec 2018
  • ||||||||||  Phase classification, Enrollment change:  Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) -  Apr 6, 2018   
    P,  N=929, Completed, 
    Recruiting --> Terminated; Terminated by sponsor Phase classification: P=N/A --> P | N=1335 --> 929
  • ||||||||||  Phase classification, Enrollment change:  Genetic Susceptibility to Factor VIII Inhibitors (clinicaltrials.gov) -  Apr 6, 2018   
    P,  N=1187, Completed, 
    Phase classification: P=N/A --> P | N=1335 --> 929 Phase classification: P=N/A --> P | N=3500 --> 1187
  • ||||||||||  staphylococcal protein A (PRTX-100) / Protalex
    Trial completion date, Trial primary completion date:  PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) -  Apr 5, 2018   
    P1b,  N=30, Recruiting, 
    Phase classification: P=N/A --> P | N=130 --> 73 Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
  • ||||||||||  vinorelbine tartrate / Generic mfg., gemcitabine / Generic mfg.
    Trial completion:  Vinorelbine and Gemcitabine in Myeloma (clinicaltrials.gov) -  Apr 3, 2018   
    P2,  N=136, Completed, 
    Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Active, not recruiting --> Completed
  • ||||||||||  Phase classification:  Genetic Analysis of Gray Platelet Syndrome (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=123, Completed, 
    Trial completion date: Dec 2017 --> Dec 2018 Phase classification: P=N/A --> P
  • ||||||||||  Trial completion, Phase classification, Enrollment change:  MOrPH: Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=9, Completed, 
    N=20 --> 7 | Recruiting --> Terminated; Slow Accrual Enrolling by invitation --> Completed | Phase classification: PN/A --> P | N=20 --> 9
  • ||||||||||  Trial completion, Enrollment change:  PTI PARI: Study of Immune Thrombocytopenia Pathogenesis: (clinicaltrials.gov) -  Mar 15, 2018   
    P=N/A,  N=89, Completed, 
    Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed | N=175 --> 89
  • ||||||||||  lenalidomide / Generic mfg., sirolimus / Generic mfg.
    Enrollment change, Trial completion date, Trial termination:  Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) (clinicaltrials.gov) -  Mar 14, 2018   
    P1/2,  N=14, Terminated, 
    Trial completion date: Oct 2017 --> Feb 2018 | Active, not recruiting --> Completed N=53 --> 14 | Trial completion date: Dec 2017 --> Jul 2017 | Active, not recruiting --> Terminated; Slow accrual